Modifi Biosciences
At Modifi Bio, we are changing the oncology treatment paradigm by developing therapeutics that uniquely target specific acquired cancer cell DNA mutations.
Employees
Enterprise value
$17—26m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
* | $30.0m | Acquisition | |
| Total Funding | 000k | ||
HighCape Partners(exited)
Connecticut Innovations(exited)
National Cancer Institute (NCI)(exited)
Advantage Capital(exited)
BrightEdge(exited)
Pathway Bioventures(exited)
Brain Tumor Society(exited)
Sontag foundation(exited)
Yale University(exited)
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads